Combination Chemotherapy and Photodynamic Therapy with Fab′ Fragment Targeted HPMA Copolymer Conjugates in Human Ovarian Carcinoma Cells
Open Access
- 27 August 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 5 (5) , 696-709
Abstract
The biological activities of sequential combinations of anticancer drugs, SOS thiophene (SOS) and mesochlorin e6 monoethylenediamine (Mce6), in the form of free drugs, nontargeted N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer−drug conjugates, P-GFLG-Mce6 and P-GFLG-SOS (P is the HPMA copolymer backbone and GFLG is the glycylphenylalanylleucylglycine spacer), and Fab′-targeted HPMA copolymer−drug conjugates, P-(GFLG-Mce6)-Fab′ and P-(GFLG-SOS)-Fab′ (Fab′ from OV-TL16 antibodies complementary to CD47), were evaluated against human ovarian carcinoma OVCAR-3 cells. Mce6, SOS, P-GFLG-Mce6, P-GFLG-SOS, P-(GFLG-Mce6)-Fab′, and P-(GFLG-SOS)-Fab′, when used as single agents or in binary combination, exhibited cytotoxic activities against OVCAR-3 cells, as determined using a modified MTT assay. The binding and internalization of P-(GFLG-Mce6)-Fab′ and P-(GFLG-SOS)-Fab′ by OVCAR-3 cells were visualized by confocal microscopy and flow cytometry. The results confirmed an enhanced biorecognition by OVCAR-3 cells of Fab′-targeted HPMA copolymer conjugates over nontargeted conjugates. The median-effect analysis and the determination of the combination index (CI) were used to describe the drug interaction and quantify the synergism, antagonism, or additivity in anticancer effects. The sequential combinations of SOS+Mce6 and P-GFLG-SOS+P-GFLG-Mce6 displayed very strong synergism to synergism in the entire range of cell inhibition levels (fa = 0.5 − 0.95). The P-(GFLG-SOS)-Fab′+P-(GFLG-Mce6)-Fab′ exhibited a strong synergism for fa values up to about 0.85, but showed synergistic effect and nearly additive effect at fa = 0.9 and 0.95, respectively. These observations support the continuation of in vivo investigations of these conjugates for the treatment of ovarian cancer.Keywords
This publication has 62 references indexed in Scilit:
- Enhanced antitumor activity of combinations of free and HPMA copolymer-bound drugsInternational Journal of Pharmaceutics, 2008
- Polymers and nanoparticles: Intelligent tools for intracellular targeting?European Journal of Pharmaceutics and Biopharmaceutics, 2008
- Polymer TherapeuticsScience, 2007
- Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination StudiesPharmacological Reviews, 2006
- Polymer conjugates as anticancer nanomedicinesNature Reviews Cancer, 2006
- Semitelechelic HPMA Copolymers Functionalized with Triphenylphosphonium as Drug Carriers for Membrane Transduction and Mitochondrial LocalizationBiomacromolecules, 2006
- Evaluation of Combination ChemotherapyClinical Cancer Research, 2004
- Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumorsNature Medicine, 2004
- A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or lightJournal of Biomaterials Science, Polymer Edition, 1994
- Antibody-directed affinity therapy applied to the immune system: In vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibodyClinical Immunology and Immunopathology, 1988